EZN-2208-04:A Phase 2 Study of EZN-2208 (PEG-SN38) Administered With or Without Cetuximab in Patients with Metastatic Colorectal Carcinoma (mCRC)

Summary:
This study will research the anticancer effects of EZN-2208 in subjects with metastatic colorectal carcinoma (that is, colorectal cancer that has spread).  Irinotecan and cetuximab are FDA-approved anticancer drugs that are used for the treatment of patients with colorectal cancer. In order to determine eligibility for this study, the genetic features of your cancer will need to be studied.
Subjects eligible for this study will receive 1 of 2 treatments:

• Group B: EZN-2208 plus cetuximab
• OR
• Group C: Irinotecan plus cetuximab

Eligibility:

1. Diagnosis of colorectal  adenocarcinoma that is metastatic or locally recurrent and nonresectable.
2. Subjects must be at least 18 years old
3. Subjects must agree to genetic testing of their tumor.
4. Subjects must not have had prior treatment with cetuximab (ErbituxP ®P), panitumumab (VectibixP ®P), or any other anti-EGFR therapies